. Author manuscript; available in PMC: 2009 Oct 16.

Published in final edited form as: N Engl J Med. 2009 Apr 16;360(16):1618–1627. doi: 10.1056/NEJMoa075760

Table 2. Development of Inhibitors to Factor VIII According to Factor VIII Haplotype among 76 Black Patients with Hemophilia A.

Variable	Development of Factor VIII Inhibitor		Odds Ratio (95% CI)
	Yes	No
Factor VIII haplotype
H4	2	0	Undefined^*
H3	7	10	2.5 (0.6–10.7)^†
H2	8	31	0.9 (0.2–3.5)^†
H1	4	14	Reference group
Haplotype group
H3+H4	9	10	3.4 (1.1–10.2)^‡
H1+H2	12	45

P = 0.79 by two-sided Fisher's exact test.

^†

The odds of having a factor VIII inhibitor were not significantly higher among the H3 or H2 patients alone than among the H1 patients.

^‡

The odds of having a factor VIII inhibitor were significantly higher among patients in the H3+H4 group than among those in the H1+H2 group.